Corrigendum: The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases
Victoria Navarro‐Compán, L. Puig, Sílvia Vidal, Julio Ramírez, Mar Llamas‐Velasco, Cristina Fernández‐Carballido, Raquel Almodóvar, José Pinto, Eva Galíndez‐Aguirregoikoa, Pedro Zarco, Beatriz Joven, Jordi Gratacós, Xavier Juanola, Ricardo Blanco, Salvador Arias‐Santiago, Jesús Sanz, Rubén Queiró, Juan D. Cañete
Abstract
Error in Figure/TableIn the published article, there was an error in Table 1 as published. The cell corresponding to ixekizumab in HS must be yellow rather than green, since it is not approved for that indication, nor phase 3 clinical development has been published. Also there is no data regarding clinical studies using tildrakizumab for IBD, so the color has been changed to yellow. The legend has been modified for clarification. The changes include the modification from “Green: Shown efficacy” to “Green: approved or shown efficacy in phase 3 clinical trials.”The corrected Table 1 and its caption “Available therapies targeting IL-17 and IL-23 in IMIDs” appear below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.